Yes, I was really surprised to see the PR today. I assume it has a lot to do with this:
the Janssen AI and Pfizer Joint Steering Committee for the AIP has decided that participants from this study who enrolled in a follow-on extension study will no longer receive doses of bapineuzumab.
I think PFE most likely felt they had obligation to release the result now, NOT until Sept.
Market Data 
Markets 
AI
